Market revenue in 2023 | USD 17.2 million |
Market revenue in 2030 | USD 22.3 million |
Growth rate | 3.8% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.47% in 2023. Horizon Databook has segmented the Middle East & Africa cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Middle Eastern countries with booming economies include Saudi Arabia, Kuwait, South Africa, and the UAE. The MEA's market for cell & gene therapy bioanalytical testing services is anticipated to expand gradually over the next several years.
The growing need for medications and the rising prevalence of diseases are among the factors responsible for market growth. Collaboration between international pharmaceutical companies, local biotech firms, academic institutions, and government agencies is essential for advancing cell and gene therapy in the MEA region.
These partnerships can help leverage resources, expertise, and funding to accelerate research, development, and access to innovative therapies. Furthermore, a lack of competition among pharmaceutical companies in the region's developing countries has resulted in an increasing number of pharmaceutical startups, which is expanding the regional market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account